The latest news and events from ECRIN and its partners

Events

Upcoming

STOA workshop: Creation of a public European medicines infrastructure: Purpose and feasibility

28 September 2022
-
28 September 2022
Online

While great progress has been made in recent years in the development of public health within the European Union (EU), the Covid-19 pandemic brought to light existing vulnerabilities in the European health response mechanism, from Member State incoordination to difficulties in manufacturing and accessing medicines, to EU research fragmentation and differences between corporate R&D choices and public health priorities.

Drug Repurposing for Rare Diseases 2022

10 October 2022
-
10 October 2022
America Square Conference Centre, London

The drug repurposing field has shifted after stepping into the limelight during the global COVID-19 pandemic. The world is beginning to care about drug repurposing and is recognising the opportunities to repurpose a drug to treat an often rare and neglected condition.

Repurposing schemes, projects and ideas are all in place to accelerate access to desperately needed medicines - the answers have been right under our noses all along!

EU-AMRI side event ICRI 2022

19 October 2022
-
19 October 2022
Brno (Czech Republic) and Online

EU-AMRI is organising a one-hour side event at ICRI 2022, held in Brno (Czech Republic). With actual case scenarios in the field of scientific health research, EU-AMRI wants to shine a light on national and international collaborations creating synergies between Research Infrastructures.

4th EULAC PerMed Summer School

15 November 2022
-
16 November 2022
Wyndham All Brook Hotel in Panama City, Panama

On 15 and 16 November 2022 the 4th EULAC PerMed Summer School will take place as a hybrid event, held in Panama City (Panama) and broadcasted online as well. The EULAC PerMed Summer School on clinical studies in Personalised Medicine aims for junior researchers and personalised medicine stakeholders, and has a specific focus on illustrating clinical studies’ gaps and challenges under different disease perspectives: infectious and neglected diseases, oncology diseases, cardiovascular and rare diseases.

EULAC PerMed Technical Workshop

17 November 2022
-
18 November 2022
Wyndham All Brook Hotel in Panama City, Panama

On 17 and 18 November 2022 EULAC PerMed organises the third and final technical workshop on clinical trials in Personalised Medicine. The workshop will focus on the clinical trial designs applied in Personalised Medicine, exploring the advantages and challenges of the different designs through use cases. The workshop will also address the challenges and opportunities of multinational collaborations in Personalised Medicine.

ECRIN CTU Day 2022

02 December 2022
-
02 December 2022
Online

ECRIN will host its 2nd CTU Day from 10-13h on 2 December 2022. The event is open to members of ECRIN national partner networks.

The program is in the process of finalisation but this years event will include feedback on the use of CTIS for multinational trials.

Stay tuned for registration and more program details

Past

HRB-NCTO ICTD - Clinical Research in Ireland 2022

12 May 2022
-
21 May 2022
Online

Registration is now open for the HRB National Clinical Trials Office (NCTO), International Clinical Trials Day, National Conference – “Clinical Research in Ireland 2022”

The NCTO International Clinical Trials Day (ICTD) event on Thursday May 12th will be a one day, on-line conference, celebrating International Clinical Trials Day, launching the calendar of ICTD events which will take place in the Clinical Research Facilities and Centres (CRF/Cs) across the network over subsequent weeks and showcasing clinical research activities across the HRB funded infrastructure.

Advanced trial designs for personalised medicine: an interactive workshop on research methods

12 May 2022
-
12 May 2022
Online

The H2020-funded PERMIT project aims to develop recommendations for robust and reproducible personalised medicine (PM) research. One of the PERMIT working groups aimed to establish standards for the design of randomised trials in PM through the involvement of multiple stakeholders, including researchers, medicines agencies and health technology assessment bodies.